key: cord-0720221-0um07o1l
authors: Tabatabai, Ali; Ghneim, Mira H.; Kaczorowski, David J.; Shah, Aakash; Dave, Sagar; Haase, Daniel J.; Vesselinov, Roumen; Deatrick, Kristopher B.; Rabin, Joseph; Rabinowitz, Ronald P.; Galvagno, Samuel; O’Connor, James V.; Menaker, Jay; Herr, Daniel L.; Gammie, James S.; Scalea, Thomas M.; Madathil, Ronson J.
title: Mortality Risk Assessment in Covid-19 Veno-Venous Extracorporeal Membrane Oxygenation
date: 2021-01-21
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2020.12.050
sha: 525eb1e19a778caae6a0d1e1f610ad341f2684dd
doc_id: 720221
cord_uid: 0um07o1l

Background A life-threatening complication of coronavirus disease 2019 (COVID-19) is acute respiratory distress syndrome (ARDS) refractory to conventional management. Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is used to support ARDS patients failing conventional management. Scoring systems to predict mortality in VV-ECMO remain unvalidated in COVID-19 ARDS. We describe the largest COVID-19 VV-ECMO single-center experience to date and assess the utility of standard risk calculators. Methods A retrospective review of a prospective database of all COVID-19 VV-ECMO patients, cannulated between March 15th and June 27th, 2020, at a single academic center was performed. Demographic, clinical, and ECMO characteristics were collected. The primary outcome was in hospital mortality; survivor and non-survivor cohorts were compared utilizing univariate and bivariate analyses. Results Forty COVID-19 ECMO patients were identified. Of the 33 patients (82.5%) off ECMO at time of analysis, 18 patients (54.5%) survived to hospital discharge and 15 (45.5%) died on ECMO. Non-survivors presented with a statistically significant higher Prediction of Survival on ECMO Therapy (PRESET)-Score (mean ± standard deviation 8.33 ± 0.8 vs. 6.17 ± 1.8, P = 0.001). The PRESET-Score demonstrated accurate mortality prediction. All patients with a PRESET-Score of ≤ 6 survived, and a score ≥ 7 was associated with a dramatic increase in mortality. Conclusions These results suggest favorable outcomes are possible in COVID-19 ECMO patients at high volume centers. This study is the first to demonstrate an association between the PRESET-Score and survival in COVID-19 VV-ECMO patients. Standard risk calculators may aid in appropriate COVID-19 ARDS patient selection for ECMO.

was first detected in the United States on January 20, 2020 and was declared a global pandemic by the World Health Organization (WHO) shortly thereafter on March 11, 2020 . While many COVID-19 patients are asymptomatic or develop only mild symptoms, a small percentage (5-12%) will develop acute respiratory distress syndrome (ARDS) requiring intubation and mechanical ventilation with a correspondingly high mortality rate (81-88%). 1, 2 Since the CESAR trial, veno-venous extracorporeal membrane oxygenation (VV-ECMO) has been widely accepted as support therapy for severe ARDS. 3, 4 VV-ECMO utilization greatly increased following the favorable results reported during the Influenza H1N1 Pandemic in 2009. 5, 6 However, evidence regarding the utility of ECMO and appropriate patient selection in refractory ARDS due to COVID-19 is lacking.

The WHO and National Institutes of Health designate ECMO as a possible therapy for patients with COVID-19 ARDS (CARDS), without suggesting routine use or providing COVID-19 specific supporting evidence. 7, 8, 9 Initial reports from Wuhan, China described poor outcomes using ECMO for COVID-19. 10,11 A pooled analysis of 17 ECMO patients from China reported a mortality of 94.1%. 12 Small studies from Italy and the United States have shown more promising results. [13] [14] [15] The mortality reported in larger pooled analyses and registry databases was approximately 45%, similar to that reported with ECMO use for ARDS prior to the COVID-19 pandemic. 16, 17 Initial reports from China described risk factors for mortality in critically ill patients with COVID-19 including age > 65 years and high Sequential Organ Failure Assessment (SOFA) score. No CARDS ECMO studies to date specifically address the previously validated Respiratory ECMO Survival Prediction (RESP), Simplified Acute Physiology (SAPS) II, or Prediction of Survival on ECMO Therapy (PRESET) Scores (Supplemental Tables 1-5) . 14, 15, [18] [19] [20] [21] [22] [23] When resources are scarce, the ability to predict which patients have a reasonable chance of benefiting from ECMO is important, both to individual patient clinical decisions, as well as healthcare system and ECMO program management.

This study describes our single center experience during the initial surge of patients during the COVID-19 pandemic. We hypothesized that application of ECMO support criteria similar to both our institutional and Extracorporeal Life Support Organization (ELSO) guidelines would be associated with prediction of survival of patients with CARDS.

After obtaining approval from our Institutional Review Board, a retrospective chart review of a prospectively maintained ECMO database was conducted. Adult (age > 18 years) CARDS patients supported with ECMO in a dedicated biocontainment unit at a large urban academic medical center between March 15, 2020 and June 27, 2020 were included.

Criteria for consideration for VV-ECMO included: hypercapnia (partial pressure of carbon dioxide [PaCO 2 ] > 60 mmHg with a pH < 7.25); inability to adequately ventilate with plateau pressure (P PLAT ) ≤ 30 cmH 2 O; and severe hypoxemia (ratio of arterial oxygen partial pressure to fractional inspired oxygen [PaO 2 /F i O 2 ] < 50 mmHg with F i O 2 > 80% for > 3 hours, or P a O 2 /F i O 2 ratio < 80mmHg with F i O 2 > 80% for > 6 hours) despite maximal ventilatory support and use of adjunctive therapies such as prone positioning, neuromuscular blockade, and inhaled pulmonary vasodilators. The decision to initiate VV-ECMO support was made after a multi-disciplinary discussion and bedside evaluation by a cardiothoracic surgeon and one or more intensivists.

Relative contraindications to VV-ECMO support included: age > 60 years, body mass index (BMI) > 50 kg/m 2 , > 10 days of mechanical ventilation, multiple organ failure, hemodialysis dependent chronic renal failure, baseline severe lung disease requiring home oxygen therapy, severe neurologic J o u r n a l P r e -p r o o f insult (e.g., cerebrovascular accident within 24-48 hours, and/or rapidly expanding hematoma or intracranial bleed), severe chronic liver disease, acute fulminant hepatic failure, and terminal illness with a low predicted one-year survival rate.

VV-ECMO cannulation was ultrasound guided and percutaneous. The typical configuration consisted of drainage from the right common femoral vein with return to the right internal jugular vein or rarely the contralateral femoral vein. The circuit consisted of a Rotaflow ® extracorporeal pump (Getinge, Gothenburg, Sweden), Quadrox-i ® adult membrane oxygenator (Getinge), and heat exchanger, and was managed by an ECMO specialist. Given the increased risk of thrombotic events in COVID-19 patients, anticoagulation with unfractionated heparin infusion was titrated to achieve a partial thromboplastin time (PTT) of 60-80 seconds for all patients. 24 A guiding principle for the management strategy of CARDS ECMO patients was to have the ability to scale ECMO support for the equivalent of a cardiac index of ~2.4 L/min/m 2 . After ECMO initiation, patients were transitioned to lung protective ventilator settings to minimize P PLAT and driving pressure. 25 Positive end expiratory pressure (PEEP) was titrated to optimize compliance while maintaining P PLAT of 20-25 cm H 2 O whenever possible. 26 Driving pressure was maintained at 10 cm 27 Refractory hypoxemia despite ECMO support, high PEEP, and high F i O 2 was managed with rescue modes of ventilation such as airway pressure release ventilation. In these cases, P PLAT was minimized to ≤ 25 cm H 2 O whenever possible. Prone positioning was used where appropriate to recruit dependent atelectasis and aid with postural drainage of respiratory secretions. 26 Variables Data collected included patient demographics, comorbidities, disease symptomatology, hospital course, treatments received, ECMO characteristics, and short-term outcomes through hospital discharge and discharge disposition. SOFA, RESP, PRESET-Score, and SAPS II were calculated utilizing the described criteria at time of ECMO initiation. [18] [19] [20] 23 Bleeding complications were defined as > 2 packed J o u r n a l P r e -p r o o f red blood cells in six hours, > 4 in 24 hours, or documentation of intracranial, auricular, nasopharyngeal, cardiac, pulmonary, gastrointestinal, genitourinary, intraabdominal, musculoskeletal, or cannula site hemorrhage requiring anticoagulation cessation and/or intervention. Thrombotic complications were defined as oxygenator change, circuit change, plasma free hemoglobin level > 20 g/dL, clotting within the veno-venous hemofiltration circuit, deep venous thrombus not related to central venous catheter or ECMO cannula, cerebrovascular accidents, or other organ infarcts on imaging. Days of mechanical ventilation was defined as time from endotracheal intubation to liberation from mechanical ventilation (extubation or tracheostomy collar > 24 hours). Dynamic compliance was calculated at cannulation and on the morning of decannulation or death utilizing the following formula:

. All tracheostomies were performed using percutaneous techniques at the bedside.

In-hospital mortality.

A descriptive analysis of the entire cohort was performed using mean and standard deviation for continuous variables and proportion (%) for categorical variables. The relationship between categorical variables and in-hospital mortality were assessed using Chi-square and Fisher's exact test. Differences in continuous variables were assessed using Analysis of Variance (ANOVA). We confirmed the ANOVA test results with nonparametric tests (Mann-Whitney U test and Kruskal Wallis test). A p-value below 0.05 was considered statistically significant. There was no difference in any complications in HIT patients compared to the cohort.

Supplemental Tables 8 and 9 display demographics, clinical characteristics, hospital course, ECMO characteristics, and short-term outcomes for survivors and non-survivors. Non-survivors had a higher PRESET-Score (mean ± standard deviation 8.33 ± 0.8 vs. 6.17 ± 1.8, P = 0.001), were more likely to have received antiretroviral treatment with remdesivir (40% vs. 5.6%, P = 0.016), and had a lower RESP although not statistically significant (2.9 ± 2.1 vs. 4.3 ± 1.9, P = 0.055). Non-survivors had a higher pre-cannulation PaCO 2 (69.7 ± 16.7 vs. 57.9 ± 14.8, P = 0.043), and lactate (3.4 ± 1.8 vs. 2 ± 0.5, P = 0.003). Furthermore, non-survivors developed more pneumothoraces after cannulation (73.3% vs. 27.8%, P = 0.009). Dynamic compliance was similar between groups at time of cannulation (20.5 ± 6.9 vs. 21.7 ± 9.7 P = 0.684); however, non-survivors never experienced an improvement in compliance as evident by a negative change in dynamic compliance at time of death (-13.3 ± 10.7 vs. 21 ± 11.7 P < 0.001).

The most statistically significant predictor of mortality was the PRESET-Score. It demonstrated 100% accuracy, superseding all other risk factors. All patients with a PRESET-Score of ≤ 6 survived and all patients with a score ≥ 7 experienced a dramatic increase in mortality of 62.5%, and up to 80% for those with a PRESET-Score of 8 and 9 (Figure 2 ).

The COVID-19 pandemic poses an unprecedented challenge for healthcare systems. While research continues regarding therapeutic options, CARDS patients have high risk of mortality, and ECMO remains a support modality for those failing conventional management and may improve survival. 1, 2, 16 Due to the resource-intensive nature of ECMO, identifying patients most likely to benefit is of great importance. For the COVID-19 pandemic, preliminary guidelines endorse the use of ECMO for patients with severe disease and high predicted mortality. 25 It has been suggested that young patients with minimal comorbidities are the highest priority for ECMO. 28 It seems reasonable that VV-ECMO be offered to CARDS patients when benefits outweigh risks and a meaningful outcome might be expected. 29, 30 The largest published pooled multicenter analysis of CARDS ECMO patients includes 331 patients with a reported survival of 54%. 16 28 This is likely multifactorial and may be related to Covid-19 diseasespecific parameters and altered care delivery during a pandemic. As the surge abates, mortality may improve as we approach normal care delivery. Survival may also improve as therapeutic options become better available and understood. Another avenue for improvement is refining CARDS ECMO patient selection criteria.

Survival prediction models such as the SAPS II score, while not specific to ECMO nevertheless have been useful in predicting non-COVID-19 ECMO patient outcomes. 31 Predicative models for VV-ECMO survival, such as RESP and PRESET-Score, are validated tools that help clinicians' decisionmaking regarding ECMO candidacy and likelihood of survival. 19, 20 However, these tools have not been evaluated in CARDS patients, and therefore during the pandemic we were not using these scores to aid decision making.

The PRESET-Score was associated with high accuracy for mortality prediction in our cohort of CARDS ECMO patients. When initially published, a low PRESET-Score (≤ 5) was associated with a 74% survival within its initial derivation cohort and was then internally validated with a 86% survival in a subsequent cohort. 20 In our study, we observed a 100% survival with a PRESET-Score ≤ 6, a dramatic increase in mortality of 62.5% with a PRESET-Score of ≥ 7, and up to 80% mortality with an increasing score ≥ 8 ( Figure 2 ). While it is not clear why the PRESET-Score was predictive and others were not, it is interesting to note that the PRESET-Score does not utilize GCS (SOFA and SAPS II), age (RESP and SAPS II), and type of admission or diagnosis (RESP and SAPS II). These factors may be subject to confounding for CARDS ECMO patients. Further confirmatory studies are needed to assess the validity of this threshold, as there appears to be a strong association between the PRESET-Score and survival. If our results are corroborated, the PRESET-Score, in conjunction with sophisticated clinical judgment, may aid in CARDS patient selection for VV-ECMO.

The RESP score, while not statistically significant in our study (P = 0.055), warrants further study in larger cohorts. 32 Interestingly, despite suggestions that the SOFA score may be of utility, neither SOFA nor SAPS II score demonstrated any utility in predicting mortality in our study. 33 This is an important finding insofar as some hospital systems have advocated the use of these scores to allocate critical care resources in Recent publication of the preliminary results of the Adaptive Covid-19 Treatment Trial indicates that remdesivir improved time to recovery compared to placebo. 35 In that trial, only 25.6% of patients were on mechanical ventilation or ECMO, so direct comparisons with our study are difficult. Our analysis revealed an association between remdesivir and mortality, but it is unclear if this association is clinically relevant. Most patients received remdesivir under emergency use authorization and not any trial protocol, during a time in the pandemic when it was scarce, introducing potential sample or selection bias. No other COVID-19 specific therapy had any statistically significant association with mortality. Larger studies are needed to examine these agents further.

The predominance of Hispanic ethnicity within our cohort may relate to socioeconomic status (SES). Disparities in health care amongst racial minority groups during this pandemic must be contextualized with SES data, which unfortunately was not available for this study. 36 Further studies are needed to address these issues.

One of the strengths of this study, in relation to previous reports, is that it describes the entire experience during the first surge of COVID-19 in a large tertiary care medical center. It is also the largest single center CARDS ECMO experience in the United States. Furthermore, less than 18 percent of our patients remain on ECMO at time of analysis, greatly reducing interim analysis bias. These factors may explain why the wide variability in mortality in previous reports was not observed in our study. [10] [11] [12] [13] [14] [15] [16] The similarity between the mortality observed in this study and the international ELSO registry statistics suggests this study can be generalized to most existent high volume ECMO centers. These results may not be generalizable to small volume ECMO centers.

J o u r n a l P r e -p r o o f size is relatively small at 40 patients. In the factors analyzed that lacked significance, and failed to reject the Null hypothesis, it is possible that this is due to lack of power rather than lack of effect.

The unprecedented COVID-19 pandemic is a crisis which places an enormous strain on healthcare systems with finite resources. Management of patients with Covid-19 is supportive, as currently there is no known cure. Patients who develop CARDS and fail conventional ventilator management may be candidates for VV-ECMO. Our results suggest that reasonable outcomes are possible at high volume ECMO centers. We also demonstrate a strong association of the PRESET-Score with mortality in CARDS VV-ECMO patients. This scoring system may help identify CARDS patients appropriate for VV-ECMO support. Refinement of scoring systems to aid in decision making regarding VV-ECMO use in CARDS remains an important focus for study and may result in more favorable outcomes. (n=4) had a 0% mortality. Patients with a PRESET-Score of 7 (n=9) had a mortality of 33.3%. Patients with a PRESET-Score of 8 (n=5) and 9 (n=10) had a mortality of 80%. Overall mortality for patients with a PRESET-Score ≥ 7 was 62.5%. Non-survivors had a higher PRESET-Score (mean ± standard deviation 8.33 ± 0.8 vs. 6.17 ± 1.8, P = 0.001). 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and metaanalysis

Extracorporeal Membrane Oxygenation for

Influenza A(H1N1) Acute Respiratory Distress Syndrome

Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis

Clinical management of COVID-19: interim guidance. (WHO Reference no. WHO/2019-nCoV/clinical/2020.5) Revised

Extracorporeal Membrane Oxygenation

Management of COVID-19 Respiratory Distress

Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series

Extracorporeal Membrane Oxygenation for Coronavirus Disease

Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports

Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19 Respiratory Distress Syndrome: Initial Experience

Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure

Extracorporeal Membrane Oxygenation Support in Severe COVID-19

Outcomes of extracorporeal membrane oxygenation support for patients with COVID-19: A pooled analysis of 331 cases

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization J o u r n a l P r e -p r o o f registry

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score

Comparison of mortality prediction models in acute respiratory distress syndrome undergoing extracorporeal membrane oxygenation and development of a novel prediction score: the PREdiction of Survival on ECMO Therapy-Score (PRESET-Score)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

Thrombosis risk associated with COVID-19 infection. A scoping review

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Driving pressure and survival in the acute respiratory distress syndrome

Extracorporeal Life Support for adults with respiratory failure and related indications: a review

Outcomes of Venovenous Extracorporeal Membrane Oxygenation When Stratified by Age: How Old Is Too Old?

VV-ECMO usage in ARDS due to COVID-19: Clinical, practical and ethical considerations

The pre-ECMO simplified acute physiology score II as a predictor for mortality in patients with initiation ECMO support at the emergency department for acute circulatory and/or respiratory failure: a retrospective study

Delivering extracorporeal membrane oxygenation for patients with COVID-19: what, who, when and how?

Calculated decisions: COVID-19 calculators during extreme resource-limited situations

Empirical Assessment of COVID-19 Crisis Standards of Care Guidelines

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Racial Health Disparities and Covid-19 -Caution and Context

The following individuals have made substantial contributions to the work reported in